Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split is a strategic move to regain compliance with Nasdaq listing requirements.
The split-adjusted trading is expected to begin on August 18, 2025.
Reverse Stock Split
The reverse split combines every 3 shares into 1 share to reduce outstanding shares.
Listing Compliance
The split aims to meet Nasdaq's minimum bid price requirement of $1.00 per share.
CEO's Statement
Interim CEO Richard Paolone emphasizes the importance of the Nasdaq listing for shareholder value.
Company Focus
Entero Therapeutics specializes in non-systemic therapies for gastrointestinal diseases, with a focus on Adrulipase development.
- The visibility and credibility associated with a Nasdaq listing are crucial for Entero Therapeutics' future growth and investor confidence.
- Reducing outstanding shares through the reverse split can impact stock price volatility and liquidity.
- The strategic decision aligns with the company's goal to enhance shareholder value and maintain a strong market presence.
The reverse stock split reflects Entero Therapeutics' commitment to regulatory compliance and shareholder value enhancement. It underscores the company's strategic approach to maintaining a listing on the Nasdaq Capital Market.